E. Vester-Blokland

Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents

I. Glick, P. Lemmens, E. Vester-Blokland, 2001, International clinical psychopharmacology.

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

D. Goff, C. Correll, S. Marder, 2009, Journal of Clinical Psychiatry.

Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine

G. L’italien, J. Newcomer, D. Crandall, 2008, Schizophrenia Research.

Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action Study

K. Behnke, J. Bäuml, A. Ravindran, 2003, Journal of clinical psychopharmacology.

The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period

J. D. den Boer, M. Boshuisen, E. Vester-Blokland, 2001, International clinical psychopharmacology.

Aripiprazole in combination with lamotrigine for the long‐term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double‐blind study (CN138‐392)

T. Ketter, R. Mcquade, R. Sanchez, 2012, Bipolar disorders.

Predictive value of early improvement in bipolar depression trials: a post-hoc pooled analysis of two 8-week aripiprazole studies.

J. Calabrese, R. Mcquade, D. Kemp, 2010, Psychopharmacology bulletin.